# Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

> **NCT07378527** · PHASE2,PHASE3 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 344 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria (CSU)

## Interventions

- **DRUG:** ICP-332 Tablets
- **DRUG:** ICP-332 placebo Tablets
- **DRUG:** ICP-332 Tablets

## Key facts

- **NCT ID:** NCT07378527
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07378527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07378527, "Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07378527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*